drugset / Trial / NCT01916993

Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

NCT01916993

Phase 1 Completed 24 enrolled Neurocrine Biosciences
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this research study is to: test the safety, tolerability, and pharmacokinetics (PK testing, the study of how the body absorbs, distributes, breaks down and eliminates a drug) of a single dose of the investigational study drug NBI-98854 in subjects with normal hepatic function or mild, moderate, or severe hepatic impairment.

Timeline

Start
2013-08
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Valbenazine Small molecule 50 mg

Indications

No indication recorded.